Disclosure controls

Section 302 of the Sarbanes-Oxley Act of 2002 requires GSK to carry out an evaluation under the supervision and with the participation of the Group's management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Group's disclosure controls and procedures as at the year-end.

The results of this latest evaluation are included in our Annual Report (PDF).